Keppra 250 mg Pharmaceutical
| Features | |
| Also known as | Levetiracetam |
| Blood pressure | Generally has no significant effect on blood pressure |
| Chemical name | (S)-О±-Ethyl-2-oxo-1-pyrrolidineacetamide |
| Dosage (medical) | Typically starts at 500 mg twice daily, adjustable based on patient response and needs |
| Dosage (sports) | Not applicable, as it is not used to enhance athletic performance |
| Effects | Reduces the frequency of seizures |
| Formula | C8H14N2O2 |
| Half-life | Approximately 6 to 8 hours |
| Hepatotoxicity | Low risk |
| Lab Test | Monitoring levels is not typically required but may be done in specific cases |
| Main action | Acts on synaptic vesicle protein SV2A, which modulates neurotransmitter release |
| Side effects | May include dizziness, fatigue, drowsiness, irritability, and coordination difficulties |
| Storage conditions | Store at room temperature, away from light and moisture |
| Strength | 250 mg |
| Substance class | Anticonvulsant |
| Trade name | Keppra |
| Use in sports | Not recognized for use in sports |
| Water Retention | Negligible |
| Manufacturer | Pharmaceutical |